Table 1.

Characteristics of included studies.

Study	Year	Design	Number	Age	Photosensitizer	Gleason	Energy (mW/cm)	Wave (nm)
Nathan TR12	2002	Single arm	14	70	Temoporfin	<4 + 4	100–150	652
Zaak D13	2003	Single arm	6	/	5-ALA	<4 + 4	/	633
Verigos K14	2006	Single arm	15	69	Motexafin lutetium	<4 + 5	150	732
Du KL15	2006	Single arm	17	69	Motexafin lutetium	<3 + 3	150	732
Moore CM16	2006	Single arm	6	66	Temoporfin	<3 + 3	150	652
Trachteberg J17	2008	Single arm	28	/	Padoporfin	/	/	763
Eymerit-Morin C18	2013	Single arm	56	63	Padeliporfin	<3 + 3	150	753
Barret E11	2013	Case control	23	66.5	Padeliporfin	<3 + 3	/	/
Moore CM19	2014	Single arm	38	63.5	Padeliporfin	<3 + 3	150	753
Azzouzi AR20	2015	Single arm	114	62.2	Padeliporfin	<3 + 4	150	753
Lebdai S21	2015	Single arm	19	64	Padeliporfin	<4 + 5	/	/
Taneja SS22	2016	Single arm	30	/	Padeliporfin	<3 + 3	/	753
Azzouzi AR10	2017	RCT	206	64.2	Padeliporfin	<3 + 3	150	753
Lebdai S23	2017	Single arm	82	63	Padeliporfin	<3 + 3	150	753

Study	Year	Dose (mg/kg)	Guidance	Biopsy negative	Pre-PSA (ng/mL)	Post-PSA (ng/mL)	Follow-up (month)	AHRQ
Nathan TR12	2002	0.15	TRUS	4	22.4	12.9	10	6
Zaak D13	2003	20	TRUS	/	7.4	4.5	6	4
Verigos K14	2006	0.5–2	TRUS	/	/	/	12	4
Du KL15	2006	0.5–2	TRUS	/	7.4	7.1	24	5
Moore CM16	2006	0.15	TRUS	0	7.3	4.1	6	3
Trachteberg J17	2008	2	Abdominal ultrasound	8	5.1	4.7	6	5
Eymerit-Morin C18	2013	/	Abdominal ultrasound	29	6.2	3.7	6	6
Barret E11	2013	/	Abdominal ultrasound	/	5.7	2.8	6	5
Moore CM19	2014	2–6	TRUS	20	/	/	6	4
Azzouzi AR20	2015	4	TRUS	78	5.6	3.5	6	8
Lebdai S21	2015	/	TRUS	/	6.3	3.7	10	5
Taneja SS22	2016	2–6	TRUS	22	3.3	2.3	12	7
Azzouzi AR10	2017	4	TRUS	101	6.2	3.2	24	8
Lebdai S23	2017	4	TRUS	62	6.1	3	6	6

AHRQ, Agency for Healthcare Research and Quality; PSA, prostate-specific antigen; RCT, randomized controlled trial; TRUS, transrectal ultrasound.